17:28 , Sep 14, 2018 |  BC Week In Review  |  Company News

ICER finds opioid use disorder treatments not cost-effective

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of three...
23:10 , Sep 10, 2018 |  BC Extra  |  Company News

ICER finds opioid use disorder treatments are not cost-effective

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of three...
17:44 , Sep 7, 2018 |  BC Week In Review  |  Company News

Alkermes in pay-for-performance deal

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence. Alkermes spokesperson Matthew Henson did not disclose...
15:12 , Aug 31, 2018 |  BC Extra  |  Company News

Alkermes in pay-for-performance deal

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence. Alkermes spokesperson Matthew Henson did not disclose...
21:20 , Jun 7, 2018 |  BC Extra  |  Politics & Policy

NIH prompts formal review of medication-assisted treatment for opioid addiction

In response to a congressional request, NIH has asked the National Academies of Sciences, Engineering, and Medicine (NASEM) to review evidence on medication-assisted treatments (MATs) for opioid use disorder to identify knowledge gaps where additional...
17:10 , Apr 6, 2018 |  BC Week In Review  |  Company News

ICER to evaluate buprenorphines for opioid disorder

The Institute for Clinical and Economic Review said it will develop a report that will compare the clinical effectiveness of three buprenorphine products to commonly used drugs for medication-assisted treatment of opioid use disorder. In its...
23:17 , Apr 5, 2018 |  BC Extra  |  Politics & Policy

ICER to evaluate buprenorphines for opioid disorder

The Institute for Clinical and Economic Review said it will develop a report that will compare the clinical effectiveness of three buprenorphine products to commonly used drugs for medication-assisted treatment of opioid use disorder. In its...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Hologic, Ostex deal

The companies will combine and co-promote their bone assessment products and develop a point-of-care NTx test for bone resorption using OSTX's Osteomark assay. The companies will market HOLX's QDR-4500C bone densitometer with a...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

AZD0424: Phase I started

Cancer Research U.K. (London, U.K) began an open-label, U.K. Phase I trial of once-daily oral AZD0424 from AstraZeneca for 28 days in about 96 patients. The dose-escalation Phase Ia portion will evaluate AZD0424 alone and...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

Alpharadin radium-223: Phase IIa data

Top-line data from the single-arm, open-label, European Phase IIa BC1-09 trial in 23 patients showed that 50 kBq/kg IV Alpharadin given once every 4 weeks for 16 weeks reduced levels of 2 biomarkers of bone...